About LianBio
LianBio is a publicly listed company based in Shanghai (China) founded in 1999. Therapeutics for cardiorenal and oncology diseases are developed. Its chief executive, as recorded, is Bing Li. Its website lianbio.com draws about 80 thousand monthly visits. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Valvular Disorders.
Company details
Founded in 1999 and headquartered in Shanghai, China, therapeutics targeting cardiorenal and oncology diseases are developed by the company. Operations focus on advancing candidates such as Infigratinib, an oral FGFR1-3 tyrosine kinase inhibitor for FGFR-driven conditions including cholangiocarcinoma and urothelial carcinoma. Additional leads include BBP-398, an allosteric SHP2 inhibitor for tumors with SHP2 activity, and Mavacamten for managing cardiac contractility.
- Headquarters Shanghai, China
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website lianbio.com
- Legal Name Lianbio
- Net Profit$4.91 M (USD)98.32as on Dec 31, 2025
- EBITDA-$1.27 M (USD)96.66as on Dec 31, 2025
- Latest Funding Round$3M (USD), Unspecified
Apr 2021
- InvestorsPfizer
& 13 more
Funding Insights of LianBio
- Total Rounds 2
- Last Round Unspecified — $3M
- First Round $310M
(Oct 2020)
- Investors Count 14
All 2 funding rounds of LianBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $3M | Unspecified | – | – | – |
| Oct 2020 | $310M | Unspecified | – | RA Capital Management, Venrock |
14 investors in total: 14 institutional.
Investors in LianBio
LianBio has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, BlackRock and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Investment holding company | 1995 | sdic.com.cn | Beijing, China | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for LianBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of LianBio
16 people are tracked at LianBio (7 in leadership, 8 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Bing Li | CEO | Leadership |
Pascal Qian | Chief Commercial Officer & GM of China | Leadership |
Kaitlin Ortega | Director, U.S. Controller | Leadership |
Jiaxin (Sylvie) Zhou | Head of Commercial Analysis & Development | Leadership |
Yen-Chao Wang | Business Development Associate Director | Leadership |
Maggie Gu | VP, Finance | Leadership |
TAO JI | VP Finance | Leadership |
Konstantin Poukalov | Founder & Executive Chairman | Board & advisors |
Neil Kumar | Director | Board & advisors |
Wei Wei Chen | Director | Board & advisors |
Zhao Yan | R&D Strategy Advisor | Board & advisors |
Elliott Levy | R&D Strategy Advisor | Board & advisors |
Mathias Hukkelhoven | R&D Strategy Advisor | Board & advisors |
Adam Stone | Director | Board & advisors |
Tassos Gianakakos | Director | Board & advisors |
Ji Chen | Svp, General Counsel | Team |
Complete people profiles for LianBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of LianBio
LianBio is a publicly listed company on the OTC with ticker symbol LIANY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Nov 2021
- Listed onNASDAQ: LIAN
- Listed entityLianBio
- Exchange sectorHealth technology
- ISINUS53000N1081
- Share price$0.05 · 2026-10-12
- Market capitalisation$6.4M
- Volume (last session)434
Financials of LianBio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $4.9M | -$1.3M | |
| 2024 | $2.5M | -$38.1M | |
| 2023 | $311.1M | -$98.2M | |
| 2022 | -$110.2M | -$124.2M | |
| 2021 | -$196.6M | -$195.3M |
Detailed financial statements for LianBio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of LianBio
4 dated milestones of LianBio across 22 years, from founding to its latest funding, stage changes and deals.
- Founded LianBio is founded.
- Funding First funding round of $310.0M.
- Funding Latest funding round, Unspecified, of $3.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of LianBio
The website of LianBio (lianbio.com) receives about 80.1K visits a month and ranks #3,555,401 among all websites worldwide, #4,589 in Biotechnology and Pharmaceuticals.
- Monthly visits80.1K
▲ 1372.6% vs previous month
- Unique visitors3.4K
per month
- Global rank#3,555,401
among all websites
- Category rank#4,589
Health · Biotechnology and Pharmaceuticals
- Bounce rate62%
- Pages per visit1.6
- Average visit1 min 16 sec
- DevicesDesktop 46% · Mobile 54%
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lianbio
Complete news archive for LianBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LianBio
LianBio was founded in 1999 and raised its 1st funding round 21 years after it was founded.
LianBio is headquartered in Shanghai, China.
Bing Li is the CEO of LianBio, as recorded in our data.
Founded in 1999 and headquartered in Shanghai, China, therapeutics targeting cardiorenal and oncology diseases are developed by the company. Operations focus on advancing candidates such as Infigratinib, an oral FGFR1-3 tyrosine kinase inhibitor for FGFR-driven conditions including cholangiocarcinoma and urothelial carcinoma. Additional leads include BBP-398, an allosteric SHP2 inhibitor for tumors with SHP2 activity, and Mavacamten for managing cardiac contractility.
Yes, LianBio is publicly traded on OTC under the ticker symbol LIANY.
LianBio has 14 investors. Key investors include Pfizer, BlackRock, T. Rowe Price, RA Capital, and Farallon Capital Management.
LianBio operates through Lianbio.